These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34218138)

  • 1. Prognostic Implications of Chemotherapy-Induced Neutropenia in Stage III Colorectal Cancer.
    Kim S; Kang SI; Kim S; Kim JH
    J Surg Res; 2021 Nov; 267():391-396. PubMed ID: 34218138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy.
    Sunaga T; Suzuki S; Kogo M; Kurihara T; Kaji S; Koike N; Harada N; Suzuki M; Kiuchi Y
    Eur J Cancer Care (Engl); 2014 May; 23(3):394-400. PubMed ID: 24033646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer.
    Roseweir AK; Park JH; Hoorn ST; Powell AG; Aherne S; Roxburgh CS; McMillan DC; Horgan PG; Ryan E; Sheahan K; Vermeulen L; Paul J; Harkin A; Graham J; Sansom O; Church DN; Tomlinson I; Saunders M; Iveson TJ; Edwards J
    J Pathol Clin Res; 2020 Oct; 6(4):283-296. PubMed ID: 32401426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer.
    Cercek A; Siegel CL; Capanu M; Reidy-Lagunes D; Saltz LB
    Clin Colorectal Cancer; 2013 Sep; 12(3):163-7. PubMed ID: 23871161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How do we apply adjuvant FOLFOX to Japanese patients with curatively resected colorectal cancer?
    Suenaga M; Matsusaka S; Watanabe T; Kuboki Y; Shinozaki E; Chin K; Mizunuma N; Ueno M; Yamaguchi T; Hatake K
    Asia Pac J Clin Oncol; 2011 Jun; 7(2):129-35. PubMed ID: 21585692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.
    Angitapalli R; Litwin AM; Kumar PR; Nasser E; Lombardo J; Mashtare T; Wilding GE; Fakih MG
    Oncology; 2009; 76(5):363-8. PubMed ID: 19321964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
    Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study.
    Akdeniz N; Kaplan MA; Uncu D; İnanç M; Kaya S; Dane F; Küçüköner M; Demirci A; Bilici M; Durnalı AG; Koral L; Şendur MAN; Erol C; Türkmen E; Ölmez ÖF; Açıkgöz Ö; Laçin Ş; Şahinli H; Urakçı Z; Işıkdoğan A
    Int J Colorectal Dis; 2021 Jun; 36(6):1311-1319. PubMed ID: 33586012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
    Uncu D; Aksoy S; Çetin B; Yetişyiğit T; Özdemir N; Berk V; Dane F; Inal A; Harputluoğlu H; Budakoğlu B; Koca D; Sevinç A; Cihan S; Durnalı AG; Özkan M; Öztürk MA; Işıkdoğan A; Büyükberber S; Benekli M; Köş T; Alkış N; Karaca H; Turhal NS; Zengin N;
    Oncology; 2013; 84(4):240-5. PubMed ID: 23392240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of chemotherapy-induced neutropenia in metastatic colon cancer patients undergoing first-line chemotherapy with FOLFOX].
    Chen Y; Wang YR; Shi Y; Dai GH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):669-674. PubMed ID: 28816286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apical Lymph Nodes in the Distant Metastases and Prognosis of Patients with Stage III Colorectal Cancer with Adequate Lymph Node Retrieval Following FOLFOX Adjuvant Chemotherapy.
    Tsai HL; Chen YT; Yeh YS; Huang CW; Ma CJ; Wang JY
    Pathol Oncol Res; 2019 Jul; 25(3):905-913. PubMed ID: 29299827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
    Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN
    Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer.
    Deng Y; Wang L; Tan S; Kim GP; Dou R; Chen D; Cai Y; Fu X; Wang L; Zhu J; Wang J
    Mol Oncol; 2015 Aug; 9(7):1341-7. PubMed ID: 25864038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
    An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
    World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer.
    Smoragiewicz M; Javaheri KR; Yin Y; Gill S
    J Gastrointest Cancer; 2014 Dec; 45(4):460-5. PubMed ID: 25012517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer.
    Chu-Yuan H; Jing P; Yi-Sheng W; He-Ping P; Hui Y; Chu-Xiong Z; Guo-Jian L; Guo-Qiang W
    BMC Cancer; 2013 Apr; 13():177. PubMed ID: 23551939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.